Fig. 1 · Structure
Documents & Downloads
Efgartigimod alfa
FcRn Blocker
Efgartigimod alfa is a humanized Fc receptor antagonist that selectively targets the neonatal Fc receptor (FcRn). By inhibiting FcRn function, Efgartigimod alfa effectively reduces serum levels of total immunoglobulin G (IgG), including pathogenic autoantibodies, without causing irreversible changes. This compound is primarily utilized in research related to generalized myasthenia gravis (gMG) and primary immune thrombocytopenia, providing insights into therapeutic mechanisms for these autoimmune conditions.
In Stock
Free Aliquoting for Your Order
Tell us your preferred amount per vial. We’ll confirm the options.
Specifications
| Manufacturer | Adooq Bioscience |
|---|---|
| Actions | Antagonist |
| CAS Number | 1821402-21-4 |
| Applications | FcRn Blocker |
| Molecular Weight | 51.28 kDa |
| Synonyms | ARGX-113 |
Storage & Solubility
In Vitro Solubility
Reported Solubility
No reported solubility data are available for this product.
Preparing Stock Solutions
| Concentration | |
|---|---|
Values use four significant digits. Prepare to the final solution volume; this is not the volume of solvent to add.
Stock preparation is unavailable for this product molecular weight.
Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.
Storage
Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.